FDA Just Approved a Groundbreaking Pancreatic Cancer Pill. Here Is Why It Matters for Nursing Home Residents.

Silver Spring, Maryland — The Food and Drug Administration has approved a first-of-its-kind treatment for pancreatic cancer, delivering a new option for patients facing one of the deadliest forms of the disease. The drug, called Rasonque (daraxonrasib), could have particular relevance for older adults in skilled nursing settings who are battling advanced cancer.

The approval, announced Wednesday, marks a significant milestone in oncology. Rasonque is a daily tablet that targets a protein called RAS, which drives tumor growth in roughly 90% to 95% of pancreatic adenocarcinoma cases. For decades, this mutation has been considered undruggable.

“Today’s approval provides a critical new option for patients facing an extraordinarily difficult and historically hard-to-treat cancer,” said Acting FDA Commissioner Kyle Diamantas in a statement.

Survival Data Shows Promise

In a randomized clinical trial involving 500 adults with previously treated metastatic pancreatic cancer, patients taking Rasonque lived a median of 13.2 months compared to 6.7 months for those receiving standard chemotherapy. That represents nearly double the survival time.

The FDA granted the drug Breakthrough Therapy and Orphan Drug designations, and approved it six and a half months ahead of the standard review deadline under the Commissioner’s National Priority Voucher pilot program.

Relevance for Long-Term Care

Pancreatic cancer disproportionately affects older adults, with the median age at diagnosis being 70. Many patients in skilled nursing facilities either have a history of cancer or are managing concurrent conditions that make aggressive treatment challenging.

Unlike traditional chemotherapy, which often requires infusion visits and carries significant side effect burdens, Rasonque is an oral medication taken once daily. That could make it more feasible for nursing home residents who may have difficulty traveling to oncology clinics.

The most common side effects include rash, diarrhea, mouth inflammation, nausea, fatigue, and decreased appetite. While these are not trivial, they differ from the systemic toxicity patterns seen with intravenous chemotherapy.

A Growing Need

Approximately 67,000 Americans are diagnosed with pancreatic cancer annually. Despite representing just over 3% of all cancer diagnoses, it accounts for a disproportionate share of cancer deaths due to late detection and limited treatment options.

The approval could signal a shift in how advanced pancreatic cancer is managed, particularly for patients who have received prior systemic therapy or are not candidates for multi-agent chemotherapy regimens. For nursing home clinicians and caregivers, the availability of an oral targeted therapy adds another tool to the palliative and therapeutic arsenal.

The drug was developed by Revolution Medicines and is expected to become available through specialty pharmacies in the coming weeks.